RU2702120C1 - Treatment of multiple sclerosis according to the method of krivopalov-moskvin - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used in treating patients with multiple sclerosis, as well as in therapy of other demyelinating diseases of the nervous system. Disclosed is a method of treating multiple sclerosis, wherein the treating substance used is apitoxin, wherein the exposure is carried out by means of bee stinging or sting, previously extracted from the bee, on biologically active points. Bee stinging areas are divided into constants, including the head and vertebral column affected daily during the course of treatment, and non-permanent, exposure on which is carried out 2–3 days later during the course of treatment, 50–70 % of total number of bees per session is put on stressed muscles, daily number of bees varies from 3 to 30. During treatment, the number of bee stinging is increased by 1-2 bees per session in the primary patient and by 3-4 bees per session in the patients, previous courses of apitherapy with anamnestic good tolerance of bee venom or patients with large body weight, duration of sting of bee sting in patient's skin is from 3 to 20 minutes.

EFFECT: according to MRI – reduced number of active centers of demyelination, reduced points of invalidisation by EDSS scale.

4 cl, 2 ex

Description

The invention relates to medicine and can be used in the treatment of patients with multiple sclerosis, as well as in the treatment of other demyelinating diseases of the nervous system.

For the treatment of multiple sclerosis (MS) at the present stage, several of the most effective pathogenetic treatment methods are used:

- hormone therapy;

- therapy with immunomodulators;

- immunosuppressive therapy.

These treatment options allow you to suspend the demyelinating process due to the impact on the pathogenetic mechanisms of destruction of the myelin sheaths.

Hormone therapy.

Therapy is carried out with adrenocorticotropic hormone (ACTH) drugs and corticosteroids. Most often, indications for the appointment of this treatment is an exacerbation of multiple sclerosis. Methods of introducing corticosteroids - pulse therapy (short courses of high doses of hormones).

Therapeutic effects of corticosteroid therapy:

- restriction of the inflammatory process;

- a decrease in the degree of destruction of myelin;

- reducing the duration of exacerbation;

- prevention of persistent neurological consequences.

(Source EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 288, para. 1).

The mechanisms of the demyelinating action of corticosteroids:

- reduction of endothelial and capillary permeability (reduction of swelling);

- stabilization of the BBB;

- reduction of lymphocyte proliferation;

- reduced production of pro-inflammatory cytokines;

- regulation of the expression level of matrix metalloproteinase in vascular endothelial cells;

- induction of apoptosis of activated leukocytes and lymphocytes;

- a change in electrolyte balance in the brain.

(EI Gusev et al. “Multiple sclerosis, a reference book”, Moscow 2009, Real Time Publishing House, p. 110, para. 2).

Natural steroid hormones include:

- ACTH (administration mechanisms - intravenously, intramuscularly);

- cortisone (mechanisms of administration - intravenously, injection into the spinal canal, oral).

Synthetic steroid hormones include:

- sinacten-depot (synthetic corticotropin) (administration mechanism - intravenous drip);

 - prednisone (intravenous drip, oral administration mechanism);

 -methylprednisolone (metipred, solu-medrol) (intravenous drip, oral administration mechanism);

- dexamethasone (intravenous drip, oral administration mechanism).

Methylprednisolone is most widely used. This drug provides a quick and active effect on target cells due to the methyl group, in contrast to prednisolone. The drug has a general and local anti-inflammatory and decongestant effect. (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 289, para. 1).

Solu-medrol is also actively used in the treatment of MS. It contains methylprednisolone sodium succinate. Short courses of solu-medrol do not lead to depletion of the hypothalamic-pituitary system (EI Gusev et al. “Multiple sclerosis, a reference book”, Moscow 2009, Real Time Publishing House, p.186, para. 1).

Side effects of glucocorticosteroids are protein synthesis disruption, osteoporosis, gastric ulcer, vascular fragility, increased blood sugar, muscle weakness, impaired cardiac function, hypertension, edema (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Publishing House -to "Oil and gas", p. 292, para. 1).

Significant disadvantages of corticosteroid treatment are:

- anti-inflammatory and immunosuppressive action is most effective only in a short period of time before and the acute stage of exacerbation of MS. (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 288, para. 2);

- corticosteroids only reduce the severity and duration of exacerbation, but do not have a beneficial effect on the course of the disease in the future (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 290, para. .2);

- repeated steroid courses increase the risk of steroid dependence, and sometimes they can stimulate an exacerbation of the demyelinating process (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 290, para. 5) ;

- when using long courses of corticosteroids, the course of MS worsens (EI Gusev et al. Multiple Sclerosis, Moscow 1997, Oil and Gas Publishing House, p. 293, para. 2).

2. PITRS - drugs that change the course of multiple sclerosis

PITRS - the collective name of drugs that can affect the course of the disease. These include two large groups of pharmacological drugs - immunomodulators and immunosuppressants.

2a. Immunomodulators are first-line treatment for multiple sclerosis. They change the immune balance in the direction of the anti-inflammatory process. This is achieved by influencing the processes of recognition by immune cells, proliferation, migration, and cytokine production (N. A. Malkova, A. P. Jerusalem “Multiple Sclerosis”, Novosibirsk 2006, State Medical University, Ministry of Health of the Russian Federation, p. 151, para. 5) .

Immunomodulators include two classes of substances:

- beta - interferons (betaferon, rebif, avonex);

- glatimerate - acetate (copaxone).

Indications for the appointment of immunomodulators ("Multiple Sclerosis. Selected Issues of Theory and Practice" edited by I. A. Zavalishin, V. I. Golovkin, Moscow 2000, p. 584, para. 2):

- patients with a clinically or laboratory confirmed reliable diagnosis of MS;

- patients with a fairly active current form of the disease, characterized by the occurrence of at least 2 exacerbations of MS in the last 2 years;

- for walking patients with an EDSS score of <5.5;

- patients aged 18 to 50 years.

Interferons β - natural human proteins, which are divided into three types: interferon alpha, beta and gamma. Types of interferons vary in receptor type and function. Interferons beta are used in the treatment of multiple sclerosis. The treatment line of interferons is represented by drugs: interferons - beta-1a (rebif, avonex) and interferons-beta-1 β (betaferon).

The main therapeutic effects of interferons:

- anti-inflammatory;

- antiproliferative,

- immunomodulatory.

The mechanism of action of interferon-beta is to inhibit the production of pro-inflammatory cytokines, slow down the proliferation of T cells, activate the function of T-lymphocyte suppressors, inhibit the production of viral proteins, stimulate the production of anti-inflammatory cytokines. (“Multiple Sclerosis. Selected Issues of Theory and Practice”, edited by I. A. Zavalishin, V. I. Golovkin, Moscow 2000, p. 585, para. 4).

Betaferon is the commercial name for interferon-beta-1b, a product of the bacterial culture of E. coli. The therapeutic effect of betaferon consists in inhibiting or modulating interferon-gamma cytokines, tumor necrosis factor-alpha, and also enhancing the suppressor function of T-lymphocytes. This limits the proliferation of T-lymphocytes and macrophages and reduces the permeability of the BBB. Betaferon also stimulates the synthesis and enhances the function of the anti-inflammatory cytokine, a transforming growth factor b, and stimulates the suppressive function of CD8 lymphocytes. (RAMS, Research Institute of Neurology "Betaferon - a new era in the treatment of multiple sclerosis", Moscow, Air-Art Publishing House 1997, p. 25, chap. 7, para. 3).

Indications for the use of betaferon:

- remitting form of MS, in the presence of at least two exacerbations in the last two years,

- Patients with a clinically confirmed diagnosis of MS.

 (RAMS, Research Institute of Neurology "Betaferon - a new era in the treatment of multiple sclerosis", Moscow, Air-Art Publishing House 1997, p. 27, para. 2).

Rebif (Avonex) - Recombinant beta-interferon-1a (product from mammalian cells). The drug has similar therapeutic effects to other beta-interferons. It is safer and more effective not only in the remitting type of flow, but also in the secondary progressive course, in contrast to betaferon. (EI Gusev et al. “Multiple sclerosis, reference book”, Moscow 2009, p. 177, para. 1). Since this recombinant protein is closer in structure to natural beta interferon, it has greater therapeutic activity than betaferon, better tolerance and fewer side effects (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil publishing house and gas ”, p. 314, para. 2).

The disadvantages of treatment with interferons are:

- frequent local and systemic adverse reactions (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 313, para. 1);

- it is possible to increase spasticity when using betaferon (“Multiple sclerosis. Selected issues of theory and practice”, edited by I. A. Zavalishin, V. I. Golovkin, Moscow 2000, p. 599, para. 4);

- Interfron courses are predominantly preventive in nature, i.e. do not restore the functions impaired as a result of previous exacerbations (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 315, para. 2);

- the formation of neutralizing antibodies when using interferons, and as a result, a decrease in the effect of treatment; (“Multiple Sclerosis. Selected Issues of Theory and Practice”, edited by I. A. Zavalishin, V. I. Golovkin, Moscow 2000, p. 588, para. 3);

- there is evidence of an increase in the activity of the pathological process in MS after the abolition of interferon-alpha (Multiple Sclerosis. Selected Issues of Theory and Practice, edited by I. A. Zavalishin, V. I. Golovkina, Moscow 2000, p. 591, para. 3 )

Copaxone (Glatimer acetate) is a synthetic polymer of the four amino acids L-alanine, L-glutamine, L-lysine, L-tyrosine. The mechanisms of its action are the stimulation of the activity of antigen-specific suppressors, the inhibition of the growth of T cells specific for the main myelin protein. This is achieved by reducing the production of IL2 gamma interferon. The drug binds to receptors on the surface of antigen-presenting cells competing with the main myelin protein. Thus, the drug plays the role of a “false target” (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 317, para. 2).

According to research data, Copaxone showed the greatest efficiency in the remitting form of multiple sclerosis in the form of reducing the frequency of exacerbations and improving and stabilizing the condition in patients (Multiple Sclerosis. Selected Issues of Theory and Practice, edited by I. A. Zavalishin, V. I. Golovkina, Moscow 2000, p. 598, para. 2).

Side effects of copaxone: local reactions after injection, general post-injection reactions in the form of facial flushing, shortness of breath, chest tightness that occur immediately after injection (Multiple Sclerosis. Selected Issues of Theory and Practice, edited by I. A. Zavalishina, V. . I. Golovkina, Moscow 2000, p. 597, paragraph 2).

The disadvantages of copaxone therapy are a decrease in its clinical and immunological activity with prolonged use (this effect is not associated with antibodies) (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 318 , paragraph 1).

2b. Immunosuppressors - cytostatics (mitoxantrone, cyclophosphamide, azathioprine, methotrexate) affect many aspects of the immunopathogenesis of multiple sclerosis. They are the drugs of choice for the secondary-progressive and primary-progressive type of disease.

Immunosuppressants by the type of their action can be divided into 2 groups:

- acting on intracellular structures - mitoxantrone (novantron),

- blocking compounds on the surface of the cells - humanized monoclonal antibodies (natalizumab, alemtuzumab).

The mechanism of action of cytostatics is based on blocking the immune response by inhibiting intracellular structures, compounds located on the surface of cells or cytokines expressed by immune cells. (N.A. Malkova, A.P. Jerusalem "Multiple Sclerosis", Novosibirsk 2006, State Medical University of the Ministry of Health of the Russian Federation, p. 151, para. 3).

Indications for the appointment of cytostatics: progressive forms of the course of multiple sclerosis, tolerant to hormone therapy and immunomodulators of the form.

Mitoxantrone - suppresses cellular and humoral immune responses. It has an immunosuppressive effect on T-helpers, cytotoxic T-cells, B-lymphocytes and macrophages, reduce the secretion of pro-inflammatory cytokines, and inhibits the production of antibodies. However, immunosuppression is not differentiated, all immune processes are suppressed, even not pathological. When using it, there are a number of serious side effects: cardiotoxicity, infection, malignancy (N.A. Malkova, A.P. Jerusalem "Multiple Sclerosis", Novosibirsk 2006, State Medical University of the Ministry of Health of the Russian Federation, p. 152, paragraph 1) .

The immunosuppressive effect of mitoxantrone is 10 times stronger than cyclophosphamide, the suppressive effect is maintained for a long time due to the long half-life of the drug. Not applicable for primary progressive course.

Methotrexate is close in therapeutic effects to azathioprine. It has a strongly immunosuppressive effect on all parts of the immune system. indications for the use of this drug are progressive forms of multiple sclerosis. By side effects, the drug is close to azathioprine (EI Gusev et al. “Multiple sclerosis, a reference book”, Moscow 2009, “Real Taii” publishing house, p. 132, paragraph 6, page 128, paragraph 2) .

Side effects of azathioprine and methotrexate: frequent and severe effects on bone marrow with leukopenia and anemia, impaired liver and gastrointestinal tract function, tumor development is not ruled out with prolonged use. (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House, p. 298, para. 2).

Significant disadvantages of treatment with cytostatics are:

- their high toxicity, especially cardiotoxicity, is associated with the limited use of drugs (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, “Oil and Gas”, p. 321, para. 2);

- immunosuppression is non-targeted, non-pathological immune processes can be suppressed. (N.A. Malkova, A.P. Jerusalem "Multiple Sclerosis", Novosibirsk 2006, State Medical University of the Ministry of Health of the Russian Federation, p. 152, para. 1);

- the effectiveness of mitoxantrone has not been proven in the primary progressive course of MS (N. A. Malkova, A. P. Jerusalem “Multiple Sclerosis”, Novosibirsk 2006, State Medical University of the Ministry of Health of the Russian Federation, p. 154, para. 1).

Thus, at present, in the treatment of multiple sclerosis, there is only therapy aimed at influencing causal factors of various origins and treating existing symptoms, but this is not enough, and therefore there is no desired result. It turns out that the disease is demyelinating, and there is practically no direct effect on the existing demyelination; there is no important direction - therapy of the demyelinating process, and what is there is only able to restrain the development of new demyelination and the existing symptoms.

That is, treatment is aimed at inhibiting the appearance of new demyelination without affecting the existing one. This is a significant mistake.

In order for multiple sclerosis to develop, a complex of causes of predispositions and related factors is necessary.

To effectively influence this disease, a simultaneous therapeutic complex is required: etiopathogenetic, myelinating, and symptomatic.

That is, to obtain a sufficient result in the treatment of multiple sclerosis, it is necessary:

I. Etiopathogenetic therapy affecting etiopathogenetic factors (causally predisposing);

II. Axonal myelinating therapy aimed at treating the disease itself (stopping the progression of demyelination and at least partial remyelination);

III. Symptomatic therapy with effects on the symptoms and syndromes developed as a result of the disease.

Only with such a comprehensive program, you can count on the expected result. In this case, we cover the disease as a whole and stepwise affect all causal, pathological and symptomatic factors.

Etiopathogenetic therapy:

Etiopathogenetic therapy of MS should be comprehensive, adequate to the etiology and severity of the course of the disease, and aimed at all links.

Etiotropic therapy is not yet perfect, including, since the exact causes of the occurrence of multiple sclerosis are unknown and there is still no truly etiotropic, i.e. eliminating the causes of disease treatment. However, much is already known about the processes of plaque formation and, especially, about autoimmune reactions, which are directly associated with a sharp deterioration in the health status of patients with multiple sclerosis and with the general course of the disease. Due to this, it is possible to influence the initial development and inhibition of the pathological process.

Existing therapy aimed at relieving or mitigating the symptoms of the disease can significantly improve the quality of life of patients and slow down the development of disability, but this is not the maximum that can be achieved.

Axonal myelinating therapy:

This therapy is aimed at restoring the integrity of the myelin sheath of the nerve fiber (neuroprotection) and damaged axons in the white and gray matter of the brain, which occur due to both insufficient nutrition of the cells forming myelin (oligodendrocytes) and additional destruction by the decay products of the myelin sheath. Treatment should also focus on demyelination and axonal damage, since remyelination restores myelin, but does not provide axonal recovery.

Symptomatic therapy:

Symptomatic therapy is aimed at the consequences of the demyelinating process and can be prescribed by a neurologist, neurophthalmologist, urologist, immunologist, electrophysiologist, neuropsychologist, psychotherapist, speech therapist, because the symptoms are varied and even the suspension of demyelination is not always able to affect the formed symptoms and syndromes.

I.e:

Etiopathogenetic therapy is a defense against demyelination.

Axonal myelinating therapy is the restoration of lost nerve functions.

Symptomatic therapy is a remedy.

Everything is interconnected and is able to give a full-fledged effect only with this triad of influences:

- etiotropic treatment is insufficient if demyelination and characteristic symptoms are already present;

- myelinating therapy without etiotropic therapy is not very effective (new demyelination cannot be allowed);

- symptomatic treatment without the first two will be unproductive (only symptoms and syndromes will be replaced, on a favorable background, new ones will come all the time).

As our experimental and clinical studies have shown, the achievement of these goals is possible only with simultaneous action: amino acid, reflex, hormonal, immunomodulating, opioid, stem stimulation, "nerve growth factor".

The objective of the present invention is to provide an effective method for the treatment of multiple sclerosis, providing simultaneous etiopathogenetic, axonal-myelinating and symptomatic treatment.

EFFECT: suspension of demyelination, receiving remyelination, restoration of lost functions as a result of a disease.

To achieve this goal, the author of the invention for the treatment of multiple sclerosis proposes a method that provides simultaneous etiopathogenetic, axonal-myelinating and symptomatic treatment, in which apitoxin is used as a treating substance and consists in simultaneous exposure:

- amino acid exposure through amino acid activation;

- hormonal effects through hormonal balance;

- immunomodulatory effects through immunomodulation with a double effect;

- reflex exposure by enhancing reflex conductivity;

- stem stimulation by activating reparative processes;

- exposure to nerve growth factor by increasing and activating oligodendrocytes;

- effects on the opioid factor by activating the opioid system.

Apitherapy is a treatment with bee venom and bee products. Apitherapy, and in particular bee venom treatment, is an alternative and quite effective therapy for multiple sclerosis.

In our practice, bee removal is successfully applied at different stages of the course of multiple sclerosis. The main therapeutic substance is the complex composition of bee venom.

Amino acid effect of bee venom:

Bee venom is a complex of peptides and enzymes. Bee venom contains 18 essential amino acids, which make up for the amino acid deficiency, and also enhance the influence of other necessary factors.

Amino acids that make up bee venom: alanine, valine, glycocol, leucine, isoleucine, serine, trionin, lysine, arginine, glutamic and aspartic acid, tryptophan, proline, tyrosine, cystine, methionine, phenylalanine, histidine. These amino acids activate the action of hormones, enzymes, stimulate various biological processes in the human body.

Peptides enhance the activity of cells of the central nervous system, more intensively pulses are conducted along the nerve pathways, including the peripheral nervous system (E. A. Ludyansky “Guide to Apitherapy”, Polygraphist, 1997, p. 26, para. 4).

Hormonal action of bee venom:

Bee venom is a stimulator of the production of its own glucocorticosteroids and stabilizes the adrenal glands.

Apitoxin melittin is able to activate the pituitary-adrenal system. This activation appears later than the action of immunostimulants. And since the adrenal glands inhibit immune responses, it is suggested that melittin will inhibit the immune response. This is the basis for the theoretical justification for the treatment of autoimmune diseases (V.N. Krylov “Bee venom properties, preparation, use”, Publishing House of the Nizhny Novgorod University of Nizhny Novgorod, 1995, p.24, para. 3).

Along with melittin, another bee venom peptide, apamine, also affects the pituitary-adrenal system. Researchers Shkenderov and Ivanov proved that, when intravenously administered to cats, the apamine peptide led to a rapid increase in the blood hormones of the adrenal glands - adrenaline and cortisol. At the same time, the level of hormones, an hour after administration, increased 8-9 times higher than the original. Hormonal action of the poison. (V.N. Krylov “Bee venom properties, preparation, application”, publishing house of Nizhny Novgorod University, Nizhny Novgorod, 1995, p. 28, para. 2).

Through stimulation of the adrenal hormones, a powerful anti-inflammatory effect is achieved locally at the site of destruction of the myelin sheath, as well as a decrease in the activity of the autoimmune process through the immunosuppressive effect of hormones.

Immunomodulatory effect of bee venom:

The authors investigated changes in the immune system of mammals on the effects of bee venom, and came to certain conclusions about the immunomodulating properties of apitoxins. Bee venom in therapeutic doses has an immunomodulatory effect. This effect is multicomponent and multidirectional: on the one hand, phagocytosis and complementary activity are stimulated, and on the other, the reaction of rosette formation and the rate of leukocyte migration are inhibited. These are the so-called specific changes in immunity. But with the introduction of “not ours”, the nonspecific protection is also activated in the body - when the bee venom enters the body, the phagocytic activity of leukocytes increases, antibodies — proteins such as lysozyme and properdine — increase.

The development of certain specific and nonspecific protective reactions in the human body are interconnected, depending on the foreignness of the agent that has got inside. Accordingly, in some cases, nonspecific protection is manifested to a greater extent, and in others, specific immunity. Due to its multicomponent nature, bee venom can exert diverse responses of the body (V.N. Krylov “Bee venom properties, production, application”, publishing house of Nizhny Novgorod University, Nizhny Novgorod, 1995, p. 76, with paragraph 3 onwards) .

The immunosuppressive effect of apitoxins can be explained by the activation of the pituitary-adrenal system with the release of catecholamines and corticosteroids into the blood. Inhibition of the antigen-antibody reaction is considered one of the mechanisms of such immunosuppression, which is especially important for autoimmune diseases, in particular for multiple sclerosis. Corticosteroids inhibit the development of autoimmune reactions at all stages: an increase in the number of lymphocytes, a decrease in their activity, movement to the lesion, etc. (V.N. Krylov “Bee venom properties, preparation, application”, publishing house of Nizhny Novgorod University, Nizhny Novgorod, 1995, p. 78, para. 2).

Thus, the inventor proposes a theory of the double effect: local immunosuppression and general immunostimulation.

True immunomodulation allows you to influence both locally, immuno-depressive, and stimulating individual parts of the immune system. Only under such conditions is it possible to resist the autoimmune process.

Bee venom allows you to achieve such a double effect due to:

- apireflexotherapy;

- apistimulation of the processes of self-regulation of the body, redistributing the immune response and immune activity.

At the same time, in the foci of demyelination, immunity is suppressed, but for the whole organism as a whole it is strengthened, increasing the defenses and resistance to foreign agents. However, for such an effect, it is important to observe the scheme and dose of the introduction of the poison in order to achieve a double effect.

Once in the body, bee venom has a general and multidirectional effect on the body. Apitoxins trigger a general adaptation syndrome in the body with the mobilization of all protective equipment, in particular activation of the secretion of the hypothalamic-pituitary system (V.N. Krylov “Bee venom properties, preparation, use”, publishing house of the University of Nizhny Novgorod, Nizhny Novgorod, 1995, pp. .40, para. 3).

In the future, under the influence of stress in the body, there is a restructuring of all functional systems, and even with a margin. The mobilization of these mechanisms is also sufficient for combating a damaging agent and functions for a long time even after the damaging agent disappears (VN Krylov “Bee venom properties, preparation, application”, publishing house of the University of Nizhny Novgorod, Nizhny Novgorod, 1995, p. 41 , paragraph 4). These adaptive reactions explain the stability and preservation of the therapeutic effect of bee venom for a long time (several months).

Reflex action of the poison:

Once in the body through the skin, the poison excites chemoreceptors of various reflexogenic zones, which leads to a change in the flow of information through afferent pathways to the central nervous system. (VN Krylov “Bee venom properties, obtaining, application”, Publishing house of the Nizhny Novgorod University of Nizhny Novgorod, 1995, p. 47, paragraph 1). The above processes prove the high therapeutic efficacy of bee venom through the BAP zone, thereby producing an effect similar to acupuncture.

The next step in normalizing the transmission of nerve impulses is neuronal synapses, where the intercellular transmission of information occurs. Under the influence of melittin, the flow of excessive excitation decreases, i.e. there is a ganglion-blocking effect through exposure to pre- and postsynaptic membranes of nerve cells (VN Krylov “Bee venom properties, preparation, use”, publishing house of Nizhny Novgorod University, Nizhny Novgorod, 1995, p. 40, para. 3). This inhibitory effect of melittin helps with spastic tetraparesis, reducing excessive pathological impulse to the extremities.

Apamine - another component of bee venom - can penetrate the BBB and act directly on the nervous tissue of the brain. The stimulating effect of apamine on the central nervous system has been established. The central effect of the peptide is accompanied by increased motor activity (VN Krylov “Bee venom properties, preparation, use”, publishing house of the University of Nizhny Novgorod, Nizhny Novgorod, 1995, p. 48, para. 2). Most likely, this action of apamine explains the significant positive therapeutic effect in muscle weakness in the limbs.

Researcher Habermann proved that apamin activates inhibitory neurons and synapses in the central nervous system, indirectly facilitating the functions of exciting neurons - general excitability, motor activity, up to seizures, increase. In addition, through other excitation agents, according to Shkenderov and Ivanov, who measured the level of the main biogenic amines, chemical intermediaries for transmitting neural information, showed that after two weeks of injection of apamine in rats at a dose of 20 μg / kg, the amount of norepinephrine and its precursors of dopamine and serotonin in the brain increased several times (VN Krylov “Bee venom properties, obtaining, application”, publishing house of the Nizhny Novgorod University of Nizhny Novgorod, 1995, pp. 27-28, paras. 3-1).

Thus, the components of bee venom are able to improve central and peripheral neuronal transmission, regulate muscle tone - reduce muscle hypotension and spasticity in the muscles, consolidate new, acquired conditioned reflexes, which is especially important during kinesitherapy.

Apamine stimulates the adrenal cortex and reticulo-limbic structures. It has an anti-inflammatory effect directly in the brain tissue, protects serum proteins from denaturation, inhibits serotonin inflammation, histoglobin and mucoprotein activity of serum complement. Proteases of the apamine peptide inhibit the action of trypsin, thrombin, papain, act like trazilol, stimulating the production of antibodies (E. A. Ludyansky “Guide to Apitherapy”, Polygraphist, 1997, p. 28, para. 2), thereby reducing the inflammatory response of the autoallergic directivity and the intensity of the destruction of myelin is suspended.

Apamine stimulates the formation of biogenic amines - norepinephrine, serotonin, dopamine (E. A. Ludyansky “Guide to Apitherapy”, Polygraphist, 1997, p. 28, para. 2). This effect is important in stabilizing the patient's psycho-emotional state.

Stem effect of bee venom:

Stem stimulation as applied to apitherapy can be considered from two perspectives:

The first, traditional is the creation of stable non-autoaggressive T-lymphocytes of the immune system of a patient with multiple sclerosis.

The second position is the effect on the rate of remyelination, through increased stem differentiation of oligodendrocytes.

It is assumed that the initial defect in the “upbringing” of thymocytes (stem cells of the immune system) begins in the thymus at the stage of recognition of “friend and foe”. In the cortico-medullary zone of the thymus, immature T-cells are trained to be able to distinguish antigens of the body itself from foreign ones.

T-cells that do not pass the test are rejected and destroyed. But if such a group of cells leaves to "work" in the body's immune system, it begins to "fight" with its own tissues, for example, myelin sheath proteins. This is how an autoimmune process is formed.

The purpose of bee venom: to restore the normal differentiation of stem cells of the immune system, in particular T-lymphocytes, to balance the number of T-lymphocyte groups, due to a qualitative decrease in the T-helper link.

The second direction in stem stimulation is stimulation of the germ layer of oligodendrocyte progenitor cells. Through their activity, bee venom can directly affect the process of remyelination (recovery of myelin fiber).

Apitoxins increase the number of oligodendrocyte precursor cells, from which new oligodendrocytes are subsequently formed, the more of them, the more intensive the process of remyelination.

Thus, bee venom:

Firstly, it affects the main pathogenetic link of the autoimmune process - proper “upbringing”, without autoaggression of T cells of the human immune system;

Secondly, through stem stimulation of oligodendrocyte progenitor cells, apitoxins accelerate axonal remyelination.

The introduction of apitoxins in certain areas of the sternum, in combination with honey applications on the sternum, stimulates a complex cascade of processes: biologically active substances are released, growth factors are formed, stem cells present in the body are involved in the process - there is an autologous stem cell transplantation.

Apitoxin therapy contributes to:

- activation of a cascade of processes in the neuroendocrine system,

- immunomodulation,

- strengthening the therapeutic potential of BAP (the opening of energy centers),

- stimulation of regeneration through stem cell activation.

Stem Cells:

- receiving a signal about the destruction of body tissues, they are sent to the affected organ, differentiating into cells of the destructible organ;

- penetrate the central nervous system, bypassing the blood-brain barrier, replace the destroyed nerve cells;

- in a planned manner, they replace tissue cells "having served their term", thereby supporting organs and systems in a working, functional mode.

Stem Cell Therapy Method:

- prolongs the life cycle of the body as a whole,

- helps to restore the functioning of functional systems (endocrine, nervous, etc.),

- enhances the overall resistance (resistance) of the body.

Apitoxic "nerve growth factor":

In the human body, there are substances that can accelerate the growth of nerves. These substances were called neurotrophins, i.e. nerve growth factors. They regulate the maturation, survival of neurons, and the targeted growth of axons. Numerous studies have shown that almost all neurotropic (with a destructive effect on the nervous system) poisons of animal origin have the ability to enhance the production of NGFs, but especially bee venom. When apitoxins enter the body through activation of the stress syndrome, the process of expression (production) of nerve growth factor is enhanced.

Bee venom is capable of:

- facilitate the entry of the FRN through the BBB,

- concentrate NGF in the damage zone - to the demyelination site,

- strengthen the reparative process by improving the trophism of the lesion site, amino acid effects.

Thus, apitoxins are able to activate the reparative processes of neurons, which gives remyelination by increasing:

- production of germ factor NGF,

- production of germinal factor BDNF,

- production of neurotrophins 3, 4/5.

Opioid effect of bee venom:

The effect of bee venom on the opioid system of the human body is a very important link in the treatment of multiple sclerosis.

The opioid system has a beneficial effect on both the ongoing physical processes of the patient and psycho-emotional, which in turn improves the physical condition even more. Opioid peptides are the main biological regulators of intercellular and tissue metabolism, are responsible for the balance of all organs and systems (homeostasis) - a “harmonizer” of the work of the whole organism. They play a significant role in the pathogenesis of the demyelinating process (one of the main mediators of a single neuroimmune system).

Bee venom can, without addiction and negative consequences, affect the human opioid system. This effect is twofold: by irritating the biologically active zone and the influence of the composition of bee venom itself through the activation of protective mechanisms, causing a positive stress syndrome, apitoxins entering the body stimulate the production of all opioid hormones: enkephalins, endorphins and dinorphins.

But the most important action in MS is apitoxin stimulation of the endorphin link of the opioid peptides. They indirectly regulate the neurotransmitter system, are responsible for neuroendocrine changes, the body's immune response, form certain emotions and the general mental state of the patient. In addition, under the influence of apitoxins, enkephalins and endorphins, they improve the process of learning new motor skills, human locomotor activity, and muscle mass growth is noted. This effect of bee venom is used for the effectiveness of apikinesitherapy (see below).

Through the neurotransmitter link of opioid peptides, apitoxins affect the regenerative capabilities of nerve tissue, participating in the process of remyelination of nerve fibers.

Side effects of apitherapy include:

- local reaction in places of beekeeping;

- general hyperthermic reaction.

According to the statistics E.A. Ludyansky he and his colleagues treated 210 patients with multiple sclerosis - 175 of them had clinical improvements (this is 83% of all treated patients) (V.N. Krylov "Bee venom properties, obtaining, use", Nizhny Novgorod publishing house University of Nizhny Novgorod, 1995, p. 168, table).

This is a rather high percentage of improvement not only in apitherapy, but also in comparison with other methods of treating MS.

Thus, according to published data, the effectiveness of betaferon within the framework of the suspension of the progression of the process fluctuates around 34%, and with the use of rebif by 69% (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, Oil and Gas Publishing House , p. 314, paras. 1-2). With the use of copaxone, a significant decrease in the number of exacerbations in patients with a remitting type of course was recorded only after two years of its constant use. (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997, “Oil and Gas” publishing house, p. 318, para. 1).

When using cytostatics, in particular, azathioprine and cyclophosphamide, their side effects outweighed the positive effects of the treatment and many patients, having familiarized themselves with their treatment results, refused to take further cytostatics (EI Gusev et al. “Multiple Sclerosis”, Moscow 1997 , Oil and Gas Publishing House, p. 299, para 1).

According to other research data, the effectiveness of the use of rebif was evaluated in 560 patients with a MS clinic - 32% after 2 years of treatment, the frequency of exacerbations decreased, the number of moderate and severe exacerbations decreased (“Multiple Sclerosis. Selected Issues of Theory and Practice” edited by I. A. Zavalishin , V.I. Golovkina, Moscow 2000, p. 590, para. 2). Other studies confirm the percentage of improvements in betaferon therapy - exacerbations decrease by 5% after 5 years of observation (RAMS, Ministry of Health of the Russian Federation “Betaferon-a new era in the treatment of multiple sclerosis”, Moscow, Air-Art publishing house, 1997, p. 16, para. 3).

Apitherapy is not inferior in therapeutic efficacy in comparison with pharmacological methods of treatment. The studies were conducted on 60 patients suffering from MS, 85% of them showed stabilization of the condition, a decrease in the symptoms of the disease ranged from 63% to 95%. (“Multiple sclerosis: current trends. Materials of the III Siberian Interregional Scientific and Practical Conference”, Novosibirsk 2007, Novosibirsk State Medical University of the Russian Federation, p. 186, para. 11).

Thus, apitherapy provides:

- amino acid effects through amino acid activation;

- hormonal effects through hormonal balance;

- immunomodulatory effects through immunomodulation with a double effect;

- reflex effect by enhancing reflex conductivity;

- stem stimulation by activating reparative processes;

- exposure to nerve growth factor by increasing and activating oligodendrocytes;

- effects on the opioid factor by activating the opioid system.

Due to this complex effect, simultaneous etiopathogenetic, axonal-demyelinating and symptomatic treatment is provided.

So, bee venom can rightfully be considered a reasonable pathogenetic method of treating MS. Apitherapy today is a potential competition with drug pathogenetic methods of treating MS.

The main methods of treatment with apitoxin:

- bee stinging;

- subcutaneous injections of finished preparations with bee venom;

- intravenous administration;

- rubbing the compounds (cream, ointment) with apitoxin;

- inhalation;

- iontophoresis (intake of substances using special devices that supply weak discharges of electricity);

- resorption under the tongue of pills with apitoxin;

- local baths with bee venom (used in the treatment of the effects of injuries, atherosclerosis, autonomic and neurocirculatory diseases);

- phonophoresis (apitoxin comes with ultrasound).

The method of bee removal proposed by the author of the present invention is as follows:

Before starting apitherapy, a biological test for sensitivity to bee venom is mandatory.

Beekeeping is done in the projection area of the adrenal gland. The sample is evaluated after 15 minutes in the area of hyperemia and papule. With a negative sensitivity to bee venom - a negative sample - hyperemia should be no more than 5 cm in diameter, papule no more than 1 cm. After negative results of a biological test, apitherapy can be started.

If the bioassay is positive or doubtful, repeat the procedure for bee stinging in the adrenal gland after 1 day with a restriction in the nutrition of products - conditional allergens.

Beekeeping in the treatment of MS can be divided into zones that either need to be “pierced every day” or alternate one zone with another. Permanent zones in the treatment of MS include: areas of the head, spinal column, with tetraparesis - areas of the arms and legs. The remaining zones (“optional”) alternate: the area of the bladder, antitremor zones, BATs of the middle meridian and axillary lines, etc.

Alternation of "optional" zones of beekeeping is carried out after 2-3 days. This treatment tactic allows you to avoid repeated bee stinging in the area of the persisting local reaction (hyperemia, swelling) from the previous "bite" of the bee.

The duration of the apitherapy course depends on the following factors:

- the duration and severity of the disease (for patients with severe motor impairment on an EDSS scale of 7 points or more, a longer course of treatment is required - this is the maximum treatment course of 20 days);

- forms of MS (as cerebellar and stem forms of MS are more difficult to treat);

- the multiplicity of apitherapy courses (the first few apitherapy courses are longer than the subsequent ones. This is due to the fact that at first it is necessary to stabilize the state and stop the demyelination process);

- individual tolerance of bee venom (in some patients, the maximum daily tolerated dose of poison, without negative changes in state, can be as little as 3-5 bees, so a larger number of bee removal sessions will be required - days to achieve the minimum course dose of poison).

Thus, the treatment time for bee stings can vary from 5 to 20 days.

The average duration of a course of apitherapy is 10 days.

Methods for dispensing bee venom:

- exposure of a bee sting in the skin for at least 20 minutes, the so-called full dose of poison. During this time, the reservoir of the poisonous gland is completely empty,

- the bee sting is removed immediately after bee stinging. This method is used in patients with hypersensitivity to bee venom, allergic patients, for areas on the body with increased swelling (face, hands, etc.),

- stinging with a sting previously extracted from a bee - “children's dose”. It is used to treat children under 8 years old, patients with exacerbation of allergic diseases, as well as for areas on the body with increased sensitivity to bee venom.

The therapeutic dose of bee venom is selected individually for each patient. The tolerance of bee venom is determined by:

- according to the local reaction at the place of beekeeping (swelling, hyperemia),

- according to the general reaction of the body in the form of weakness, chills, fever or more severe symptoms.

If the above symptoms appear, the apitherapist reduces the number of bee stings per day, changes the exposure of the sting, or takes a break in the procedures for bee stings for several days.

On average, the minimum course therapeutic (curative) dose of 60 beekeeping.

The average daily dose of poison is 10-12 bee-killers.

However, nevertheless, the number of bee removal is not always decisive, since individual characteristics must also be taken into account.

An increase in the number of bee removal is carried out on average by 1-2 bees per session in the primary patient, from 3-4 in patients who underwent early apitherapy courses with an anamnestically good tolerance of bee venom or large body weight. An increase in the number of bee stings from session to session is carried out before the appearance (or increase) of a local reaction at the place of beekeeping. Therefore, the maximum daily number of “planted” bees can vary from 3 to 15-20, and in some patients with good tolerance of bee venom and up to 30 pieces.

The main symptom complex of the disease leaves 50-70% of the total number of bees per session, for example: in a patient with spastic lower paraparesis, the daily dose of 10 bees, then 6 bees are placed on the tense muscles, the rest are distributed on the head - 2 and on the spine - 2.

From 1 to 4 bee stings are done in the head areas in one session, on average 2.

Regions of bee stings along the lower extremities: according to the projection of the sciatic nerve, anatomically corresponds to the middle of the buttock, the middle of the sublingual fold, the middle of the back of the thigh, the popliteal fossa on the outside, the middle of the calf muscle. In addition, bees are placed on the lateral external surfaces of the thigh and lower leg, the anterior surface of the thighs, the projection of the Achilles tendon, the lateral lateral and medial calcaneal region, between the base 1 and 2, as well as 4 and 5 toes of the feet, arch of the feet, plantar surface of the feet, rear of the feet.

Areas of beekeeping on the upper extremities: lateral lateral surface of the shoulders, inner region of the forearms, rear of the elbow joints, rear of the wrist joints, wrist joints on the inside, tenor and hypotenor of the hand, center of the palm, fingertips.

Areas of bee removal in pelvic disorders: suprapubic area (with severe symptoms of bee removal in this area are carried out every other day), lumbosacral area.

With cerebellar symptoms: projection of the medulla oblongata, mastoid processes, collar zone, region of biceps, inner region of the forearm, calf muscles, rear of the ankle joints.

The projections of bee-tucking correspond to the following BAP: spine - bladder meridian: paravertebral from V11 to V30, sacrum from V30 to V35, posterior median meridian: from T1 to T14 (between the spinous processes of the vertebrae).

BATs of the head - the meridian of the stomach: E8 (between the frontotoparietal region, determined by chewing movements), the meridian of the bladder: V9 (occipital tubercles), V8 (parietal tubercles), the meridian of three cavities - TR18 (mastoid processes), the meridian of the gall bladder - VB20 (under the occipital tubercles), VB4 (frontal tubercles), VB3 (temporal region), posterior median meridian: T19 (crown), T16 (projection of the medulla oblongata), T22 (between the parietal tubercles), PC13 (lower edge of the mastoid process).

The collar zone is the small intestine meridian: from IG15 to IG10, the meridian of three cavities is TR14-TR15.

Zones of the lower extremities. The course of the sciatic nerve is the meridian of the bladder: V36 (middle of the sublingual fold); V 37 and V38 (middle of the back of the thigh); V39, V40 (popliteal fossa); from V55 to V59 (middle of the calf muscle); V60-V61 (Achilles tendon); from V 64 to V 67 (lateral surface of the foot).

The calf muscle is PN83-PN86.

The front surface of the thigh and lower leg is the meridian of the stomach from E30 to E44. The projection of the rectus femoris muscle (the “anterior” thigh muscle) from E 31 to E34. Inner thigh surface, projection of the tailor muscle RP 11, RP10.

The inner (medial) side of the leg is the meridian of the spleen and pancreas: from RP11 to RP5.

The outer (lateral) side of the leg is the meridian of the gallbladder VB31-VB33 (thigh), VB34-VB39 (lower leg).

The front lateral surface of the thigh is PC159, PC158, PC157.

Internal projection of the foot: meridian of the spleen and pancreas from RP4 to RP1.

Between the 4 and 5 toes of the foot - the meridian of the gallbladder: VB 43.

Between 1 and 2 toes of the foot - liver meridian: F1.

The sole surface of the foot is PC123.

Zones of the upper extremities. The upper third of the biceps is the pericardium meridian: MC2. The middle of the biceps is PN 68.

The middle of the ulnar fold is the pericardial meridian: MC3.

The inside of the forearm is the pericardial meridian: from MC4 to MC6.

The inside of the wrist joint is the pericardial meridian: MC7.

Zone of the pelvic organs. Crotch - anterior median meridian: J1.

The bladder region (suprapubic region) is the anterior median meridian: J3.

Zones of the anterior median meridian. The epigastric region is the anterior median meridian: J14-J16.

The projection of the solar plexus is the anterior median meridian: J14.

The projection of the sternum is the anterior median meridian: J17-J21.

Thymus projection - Anterior median meridian: J20.

The mid-clavicular line is the stomach meridian: E12, E13, E14, E15, E16, E17, E18, E19. BATs for beekeeping on the left from E16 to E18 (projection of the heart) are excluded.

Vision - the meridian of the bladder: V2 (inner angle of the superciliary arch), the meridian of the gallbladder VB1 (outer corner of the eye), the meridian of the three cavities - TR 23 (outer corner of the superciliary arch).

Given the chronic nature of the disease, apitherapy courses are recommended twice a year, with a progressive, malignant course, apitherapy can be carried out 1 time in 3 months.

Clinical examples.

Example 1

Patient Svetlana R., born in 1976

Diagnosis: multiple sclerosis, secondary progressive course, lower paraparesis syndrome, pelvic disturbance syndrome.

Anamnesis of life and disease. Heredity is not burdened. Pregnancy in the mother proceeded with toxicosis of the second half. Delivery on time, without features. Development by age. The dispensary was not registered with specialists. Vaccination by age. At 5 years old she had chickenpox. Sick SARS 1-2 times a year. From middle school, scoliosis of the thoracic spine. She received a secondary special education - an accountant, worked in her specialty. Married since 1986. Has two children. Pregnancy and childbirth proceeded without pathologies. I had no chronic diseases. In February 2008, she had the flu complicated by bronchitis. A week after recovery, I felt weakness in my legs (“they don’t obey,” like “not their own,” “you walk like on inflated soles”). After examination on MRI, foci of demyelination were detected, and therefore was sent to in-patient treatment in the neurological department with a diagnosis of demyelinating disease. After hormone treatment, the condition improved, but there was a slight weakness in the left leg. Subsequently, the diagnosis was made: multiple sclerosis, remitting course. Member of the dispensary in the office of multiple sclerosis. Since 2009, she has been receiving PITRS drugs - interferon - beta (betaferon). The disease proceeds with an exacerbation 1-2 times a year, characterized by weakness in the legs, impaired walking function. After hormone therapy, as a rule, an improvement occurred, but with partial preservation of paresis of the lower extremities. In general, progression of the disease was noted - negative symptoms were present during periods of remission, and since 2013, pelvic disorders joined: incontinence and difficulty urinating. Subsequently, hormone therapy gave an increasingly less pronounced improvement.

In May 2014, she turned to the IPA International Clinic and underwent a treatment and rehabilitation apitherapy course lasting 10 days. Complaints on admission to general weakness, numbness in the lower extremities, walking only with the help of others, pathological urges and urinary incontinence. Somatic status of organs without features, with the exception of difficulty urinating. Neurological status: speech, smell, taste and eyesight without features. Nystagmus is absent. Painful, tactile sensitivity saved. Hearing, swallowing are not disturbed. Meningic signs are absent. The volume of passive movements in the limbs is complete. Restriction of active movements in the lower extremities. Muscle strength in the hands of 5 points. In the lower extremities: muscle strength of the left 2 points, right 3 points. The muscle tone of both lower extremities is reduced. Tendon reflexes from the legs are elevated. The abdominal reflexes are lively. Pose Romberg performs with difficulty. Walking with outside help. Violation of the function of urination according to the central type (imperative urges, delay and incontinence). On an extended disability scale, EDSS is 6.5 points.

Treatment and follow-up. She underwent therapy under the Apitox treatment and rehabilitation program, with a gradual increase in the dose of bee venom, as well as preparations based on propolis, royal jelly, pollen.

She tolerated apitherapy without side effects (lack of temperature and local reaction). On the 3rd day of treatment, a decrease in general weakness, lethargy was noted. On the 5th day of treatment, subjectively noted an increase in muscle strength in the legs, improved gait with minimal extraneous support. On day 7, the urge to urinate decreased, it became better to control the process of urination. By day 10, the patient could walk up to 20 m on her own.

Follow-up observation. After the end of treatment, a repeated course was recommended for this program six months later.

After 7 months, she repeated the course of treatment. In total, 4 courses of inpatient treatment took place at the IPA Clinic. Over the 4 years of follow-up, disease progression was not observed, MRI results - from 2014 without negative dynamics, the number of active foci decreased, there was no increase in clinical symptoms of the disease. On the disability scale EDSS, there is a decrease in scores to 4.5. In the neurological state, a positive dynamics was observed during the observation without deterioration.

Example 2

Patient Sergey N., born 1996, student.

Diagnosis: multiple sclerosis, remitting course, remission.

Anamnesis of life and disease. Heredity is not burdened. Pregnancy in the mother proceeded with toxicosis of the first and second half. Delivery complicated, prolonged.

Vaccination by age, without complications. Allergic history is not burdened. Since 10 years she has been engaged in the swimming section. In March 2016, he fell on his back in training, having hit the back of his head. After a month, vision on the left eye began to decrease with a partial loss of visual fields. After consulting an ophthalmologist, an MRI scan was performed (according to MRI, 11 active foci of demyelination were detected). He underwent inpatient treatment in the neurological department with a diagnosis of multiple sclerosis, retrobulbar neuritis. Results of treatment: partial restoration of visual fields, visual acuity in the left eye remained reduced.

In July 2016, he turned to the IPA clinic with complaints of decreased vision in the left eye and the feeling of small black spots with the left eye. At admission: Somatic status: normosthenic physique, for organs without pathology. Neurological status: speech, smell, taste without features. Nystagmus is absent. Decreased vision in the left eye. Painful, tactile sensitivity saved. Hearing, swallowing are not disturbed. Meningic signs are absent. The volume of passive and active movements in the limbs is full. Muscle strength and muscle tone in the upper and lower extremities 5 points. Tendon and abdominal reflexes are normal. Coordination does not suffer. Gait independent without difficulty. Urination and bowel movements are not difficult.

Treatment and follow-up. He completed a treatment and rehabilitation course under the Apitox program lasting 10 days. By the end of the course of treatment, vision improved.

Follow-up observation. A repeated course in six months is recommended.

Subsequently, regularly every six months I took repeated courses of apitherapy lasting 7 days. In total, I completed 5 courses. In dynamics according to the neurological status, no deterioration was observed. After the first course of apitherapy, the vision in the left eye was restored to 0.9, the feeling of small black spots in the left eye stopped to one spot and it decreased in size. To date, remission of the disease remains.

Claims (4)

1. A method of treating multiple sclerosis, in which apitoxin is used as a treating substance and consists in simultaneous exposure to: amino acid, hormonal, immunomodulatory, reflex, opioid, stem stimulation and effects on nerve growth factor, providing simultaneous etiopathogenetic, axonal-myelinating and symptomatic treatment , while the effect is carried out by means of bee stings or a sting previously extracted from a bee on biologically active points, places human obstruction is divided into constants, which include the head area and spinal column, the effects of which are carried out daily during the course of treatment, and non-permanent, the effects of which are carried out after 2-3 days during the course of treatment, 50-70% of the total number of bees per session, the daily number of bees varies from 3 to 30, while in the process of treatment an increase in the number of bee removal is carried out by an average of 1-2 bees per session in the primary patient and by 3-4 bees per session in patients, previously passed After apitherapy courses with an anamnestically good tolerance of bee venom or patients with a large body weight, the duration of the stay of a bee sting in the patient's skin is from 3 to 20 minutes. 2. A method of treating multiple sclerosis according to claim 1, characterized in that with tetraparesis, the permanent zones that are affected daily are additionally the zones of the arms and legs. 3. A method of treating multiple sclerosis according to claim 2, characterized in that the duration of treatment is from 5 to 20 days. 4. A method of treating multiple sclerosis according to claim 2, characterized in that the number of apitherapy courses is at least two times a year.